{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:02Z","timestamp":1790346662525,"version":"4.1.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0124325","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T13:57:53Z","timestamp":1429711073000},"page":"e0124325","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson\u2019s Disease"],"prefix":"10.1371","volume":"10","author":[{"given":"Sandy","family":"Stayte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Rentsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Vissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/mds.25344","article-title":"Trophic factor gene therapy for Parkinson&apos;s disease","volume":"28","author":"JH Kordower","year":"2013","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1097\/00001756-199607290-00026","article-title":"Strong induction of activin expression after hippocampal lesion","volume":"7","author":"YP Tretter","year":"1996","journal-title":"Neuroreport"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0306-4522(95)00413-0","article-title":"Sequential patterns of inhibin subunit gene expression following hypoxic-ischemic injury in the rat brain","volume":"70","author":"M Lai","year":"1996","journal-title":"Neuroscience"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/77548","article-title":"Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo","volume":"6","author":"YP Tretter","year":"2000","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/j.1460-2075.1995.tb07052.x","article-title":"TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity","volume":"14","author":"K Krieglstein","year":"1995","journal-title":"EMBO J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1471-4159.2007.04785.x","article-title":"The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases","volume":"103","author":"L Kupershmidt","year":"2007","journal-title":"J Neurochem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/stem.80","article-title":"Activin A is essential for neurogenesis following neurodegeneration","volume":"27","author":"A Abdipranoto-Cowley","year":"2009","journal-title":"Stem Cells"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Cenci MA, Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson&apos;s disease in rats and mice. Curr Protoc Neurosci. 2007; Chapter 9: Unit 9 25.","DOI":"10.1002\/0471142301.ns0925s41"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2818.1987.tb02837.x","article-title":"The efficiency of systematic sampling in stereology and its prediction","volume":"147","author":"HJ Gundersen","year":"1987","journal-title":"J Microsc"},{"key":"ref10","author":"G Paxinos","year":"2001"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"JM Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tips.2013.07.005","article-title":"Mechanisms of dopamine transporter regulation in normal and disease states","volume":"34","author":"RA Vaughan","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson&apos;s disease","volume":"21","author":"E Bezard","year":"2001","journal-title":"J Neurosci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1046\/j.1460-9568.1999.00764.x","article-title":"Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter","volume":"11","author":"M Jaber","year":"1999","journal-title":"Eur J Neurosci"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1073\/pnas.95.7.4029","article-title":"Profound neuronal plasticity in response to inactivation of the dopamine transporter","volume":"95","author":"SR Jones","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","first-page":"113","article-title":"Advances in non-dopaminergic treatments for Parkinson&apos;s disease","volume":"8","author":"S Stayte","year":"2014","journal-title":"Front Neurosci"},{"key":"ref17","article-title":"Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","article-title":"Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients","volume":"80","author":"RT Bartus","year":"2013","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson&apos;s disease and nonhuman primate brains","volume":"26","author":"RT Bartus","year":"2011","journal-title":"Mov Disord"},{"key":"ref20","unstructured":"PRNewswire. Ceregene reports data from Parkinson&apos;s disease Phase 2b study. PRNewswire. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.prnewswire.com\/news-releases\/ceregene-reports-data-from-parkinsons-disease-phase-2b-study-203803541.html\" xlink:type=\"simple\">http:\/\/www.prnewswire.com\/news-releases\/ceregene-reports-data-from-parkinsons-disease-phase-2b-study-203803541.html<\/ext-link>"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","article-title":"Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson&apos;s disease","volume":"46","author":"JH Kordower","year":"1999","journal-title":"Ann Neurol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/ejn.12459","article-title":"Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson&apos;s disease","volume":"39","author":"SR Stott","year":"2014","journal-title":"Eur J Neurosci"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/neur.1995.0016","article-title":"6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death","volume":"4","author":"BS Jeon","year":"1995","journal-title":"Neurodegeneration"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat","volume":"59","author":"H Sauer","year":"1994","journal-title":"Neuroscience"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"8935","DOI":"10.1073\/pnas.92.19.8935","article-title":"Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion","volume":"92","author":"H Sauer","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1046\/j.1460-9568.2000.00274.x","article-title":"Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor","volume":"12","author":"D Kirik","year":"2000","journal-title":"Eur J Neurosci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1006\/exnr.1999.7296","article-title":"Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model","volume":"161","author":"C Rosenblad","year":"2000","journal-title":"Exp Neurol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1046\/j.1460-9568.1999.00566.x","article-title":"Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson&apos;s disease after administration into the striatum or the lateral ventricle","volume":"11","author":"C Rosenblad","year":"1999","journal-title":"Eur J Neurosci"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1523\/JNEUROSCI.16-22-07206.1996","article-title":"Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson&apos;s disease","volume":"16","author":"C Winkler","year":"1996","journal-title":"J Neurosci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/hum.2008.201","article-title":"Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys","volume":"20","author":"JL Eberling","year":"2009","journal-title":"Hum Gene Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.expneurol.2003.08.007","article-title":"Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus)","volume":"184","author":"A Eslamboli","year":"2003","journal-title":"Exp Neurol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2013.04.011","article-title":"Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)","volume":"58","author":"CD Herzog","year":"2013","journal-title":"Neurobiol Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/hum.2008.137","article-title":"Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys","volume":"20","author":"LC Johnston","year":"2009","journal-title":"Hum Gene Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.gt.3301682","article-title":"Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson&apos;s disease","volume":"9","author":"L Wang","year":"2002","journal-title":"Gene Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0124325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T19:40:34Z","timestamp":1566589234000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0124325"}},"subtitle":[],"editor":[{"given":"Joohyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0124325","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]}}}